Comanche Biopharma Successfully Concludes Oversubscribed $75M Series B Funding Round to Propel Mission in Pioneering the First Treatment Addressing the Fundamental Cause of Preeclampsia
- Jan 17, 2024
- 1 min read
Concord, MA, January 17, 2024 (Globe Newswire) -- Comanche Biopharma Corp. closes an oversubscribed $75 million Series B financing, marking a significant milestone in advancing the company's mission to develop and make globally available the first treatment targeting a root cause of preeclampsia.
Read full article here.
Comments